CompletedNCT00192023

Atomoxetine 0.5 mg/kg or placebo for oppositional symptoms in ADHD

About this title

Medication studyAges 6–15Italy

The study in practice

Understand this study

This study was for people with ADHD. Listed age limits: 6 years to 15 years. Other eligibility criteria applied.

Listed locations: Alessandria and 11 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateOctober 2004

Recruitment status: Completed
Enrollment listed in the registry: 139
Sponsor: Eli Lilly and Company
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Italy
Age range: From 6 Years to 15 Years
Official registry ID: NCT00192023
Official title: Show the full official title
An Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder

Completed

Alessandria · Bari · Cagliari

9 more locations

FAQ

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including atomoxetine 0.5 mg/kg/day, placebo, atomoxetine 1.2 mg/kg/day and atomoxetine 1.2-1.4 mg/kg/day.

Who was this study for?

This study was for people with ADHD. Listed age limits: 6 years to 15 years. Other eligibility criteria applied.